A review of minodronic acid hydrate for the treatment of osteoporosis

Shinji Tanishima, Yasuo MorioDepartment of Orthopedic Surgery, Misasa Onsen Hospital, Misasa, Tottori, JapanAbstract: Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in Japan. With regard to inhibition of bone resorption, minodronic acid hydrate...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tanishima S, Morio Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Osteoporosis 　Minodronic acid hydrate Treatment Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/d0ab5805866f45c6b788d4b34bb2c585
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0ab5805866f45c6b788d4b34bb2c585
record_format	dspace
spelling	oai:doaj.org-article:d0ab5805866f45c6b788d4b34bb2c5852021-12-02T03:15:40ZA review of minodronic acid hydrate for the treatment of osteoporosis1178-1998https://doaj.org/article/d0ab5805866f45c6b788d4b34bb2c5852013-02-01T00:00:00Zhttps://www.dovepress.com/a-review-of-minodronic-acid-hydrate-for-the-treatment-of-osteoporosis-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Shinji Tanishima, Yasuo MorioDepartment of Orthopedic Surgery, Misasa Onsen Hospital, Misasa, Tottori, JapanAbstract: Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in Japan. With regard to inhibition of bone resorption, minodronic acid hydrate is 1000 times more effective than etidronic acid and 10–100 times more effective than alendronic acid. Clinical trials conducted to date have focused on postmenopausal female patients suffering from primary osteoporosis. In these trials, 1 mg of oral minodronic acid hydrate was administrated once daily, and a significant increase was observed in lumbar-spine and hip-joint bone density 1–2 years after administration. All markers of bone metabolism urinary collagen type 1 cross-linked N-telopeptide, urinary free deoxypyridinoline, serum bone alkaline phosphatase, and serum osteocalcin were decreased. The incidence rate of new vertebral and nonvertebral fractures was also decreased. Therefore, effectiveness in fracture prevention was confirmed. A form of minodronic acid (50 mg) requiring once-monthly administration has been developed and is currently being used clinically. A comparative study between this new formulation and once-daily minodronic acid (1 mg) showed no significant differences between the two formulations in terms of improvement rates in lumbar-spine and hip-joint bone density, changes in bone metabolism markers, or incidence of side effects. This indicates the noninferiority of the monthly formulation. Side effects such as osteonecrosis of the jaw or atypical femoral fractures were not reported with other bisphosphonates, although it is believed that these side effects may emerge as future studies continue to be conducted. On the basis of studies conducted to date, minodronic acid hydrate is considered effective for improving bone density and preventing fractures. We anticipate further investigations in the future.Keywords: osteoporosis, minodronic acid hydrate, treatment, bisphosphonateTanishima SMorio YDove Medical PressarticleOsteoporosis　Minodronic acid hydrateTreatmentGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 8, Pp 185-189 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Osteoporosis 　Minodronic acid hydrate Treatment Geriatrics RC952-954.6
spellingShingle	Osteoporosis 　Minodronic acid hydrate Treatment Geriatrics RC952-954.6 Tanishima S Morio Y A review of minodronic acid hydrate for the treatment of osteoporosis
description	Shinji Tanishima, Yasuo MorioDepartment of Orthopedic Surgery, Misasa Onsen Hospital, Misasa, Tottori, JapanAbstract: Minodronic acid hydrate was the first bisphosphonate developed and approved for osteoporosis treatment in Japan. With regard to inhibition of bone resorption, minodronic acid hydrate is 1000 times more effective than etidronic acid and 10–100 times more effective than alendronic acid. Clinical trials conducted to date have focused on postmenopausal female patients suffering from primary osteoporosis. In these trials, 1 mg of oral minodronic acid hydrate was administrated once daily, and a significant increase was observed in lumbar-spine and hip-joint bone density 1–2 years after administration. All markers of bone metabolism urinary collagen type 1 cross-linked N-telopeptide, urinary free deoxypyridinoline, serum bone alkaline phosphatase, and serum osteocalcin were decreased. The incidence rate of new vertebral and nonvertebral fractures was also decreased. Therefore, effectiveness in fracture prevention was confirmed. A form of minodronic acid (50 mg) requiring once-monthly administration has been developed and is currently being used clinically. A comparative study between this new formulation and once-daily minodronic acid (1 mg) showed no significant differences between the two formulations in terms of improvement rates in lumbar-spine and hip-joint bone density, changes in bone metabolism markers, or incidence of side effects. This indicates the noninferiority of the monthly formulation. Side effects such as osteonecrosis of the jaw or atypical femoral fractures were not reported with other bisphosphonates, although it is believed that these side effects may emerge as future studies continue to be conducted. On the basis of studies conducted to date, minodronic acid hydrate is considered effective for improving bone density and preventing fractures. We anticipate further investigations in the future.Keywords: osteoporosis, minodronic acid hydrate, treatment, bisphosphonate
format	article
author	Tanishima S Morio Y
author_facet	Tanishima S Morio Y
author_sort	Tanishima S
title	A review of minodronic acid hydrate for the treatment of osteoporosis
title_short	A review of minodronic acid hydrate for the treatment of osteoporosis
title_full	A review of minodronic acid hydrate for the treatment of osteoporosis
title_fullStr	A review of minodronic acid hydrate for the treatment of osteoporosis
title_full_unstemmed	A review of minodronic acid hydrate for the treatment of osteoporosis
title_sort	review of minodronic acid hydrate for the treatment of osteoporosis
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/d0ab5805866f45c6b788d4b34bb2c585
work_keys_str_mv	AT tanishimas areviewofminodronicacidhydrateforthetreatmentofosteoporosis AT morioy areviewofminodronicacidhydrateforthetreatmentofosteoporosis AT tanishimas reviewofminodronicacidhydrateforthetreatmentofosteoporosis AT morioy reviewofminodronicacidhydrateforthetreatmentofosteoporosis
_version_	1718401886723244032

A review of minodronic acid hydrate for the treatment of osteoporosis

Ejemplares similares